Endometrial Cancer Mutation Profiling for Platinum Response Selection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for endometrial cancer, particularly platinum-based chemotherapy, are not tailored to individual patient responses, leading to inefficiencies due to the majority of cases being HR proficient, necessitating a more personalized molecular-based therapy.

Innovation Solution

Assessing genetic markers such as mutations in FBXW7, PPP2R1A, CCNA2, POLE, and p53 nucleic acids, and their expression levels to predict platinum-based chemotherapy responsiveness, and administering targeted cancer treatments like platinum-based therapies or alternatives based on these assessments.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If platinum-based chemotherapy is administered to all endometrial cancer patients, then treatment coverage is maximized, but treatment efficacy decreases due to HR proficiency in majority of cases

Engineering Contradiction:

Improvetreatment efficacyVSAvoidpersonalized treatment adaptability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent segments endometrial cancer patients into distinct molecular subgroups based on genetic markers (HR status, FBXW7 mutations, PPP2R1A mutations, CCNA2 expression). This segmentation enables tailored treatment strategies for each subgroup, improving overall treatment efficacy by avoiding ineffective platinum-based chemotherapy in HR-proficient patients while identifying those who will benefit from it.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent changes the treatment selection parameter from a uniform approach to a molecularly-driven approach. By measuring specific genetic parameters (HR pathway status, FBXW7 mutation status, PPP2R1A mutation status, CCNA2 expression levels), the treatment regimen is dynamically selected to match the molecular profile of each patient's tumor, thereby resolving the contradiction between broad coverage and personalized efficacy.

Inventive Principle:

Principle #35Parameter changes

2Measurement precision

If molecular-based therapy assessment is implemented, then personalized treatment precision is improved, but diagnostic complexity and cost increase

Engineering Contradiction:

Improvetreatment prediction precisionVSAvoiddiagnostic system complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent performs preliminary molecular assessment of endometrial cancer tumors using a defined panel of genetic markers (HR pathway genes, FBXW7, PPP2R1A, CCNA2) before treatment selection. This preliminary action of measuring molecular profiles upfront enables accurate prediction of platinum-based chemotherapy responsiveness, providing precise treatment guidance while using a standardized, relatively simple diagnostic panel that can be implemented in clinical settings.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS12601742B2Methods and materials for treating endometrial cancer by assessing combinations of mutations and expression levels

Publication Date: 2026.04.14 THE UNIVERSITY OF IOWA RESEARCH

AI summary

This document relates to methods and materials for assessing and/or treating mammals (e.g., humans) having endometrial cancer. For example, methods and materials for identifying endometrial cancers likely to respond to a particular cancer treatment (e.g., a platinum based cancer therapy) are provided. This document also relates to materials and methods for using one or more cancer treatments to treat a mammal (e.g., a human) identified as likely to respond to a particular cancer treatment.